Cell Death and Disease (Jun 2024)

RANKL/RANK signaling recruits Tregs via the CCL20–CCR6 pathway and promotes stemness and metastasis in colorectal cancer

  • Jing Ouyang,
  • Shuang Hu,
  • Qingqing Zhu,
  • Chenxin Li,
  • Tingting Kang,
  • Wenlin Xie,
  • Yun Wang,
  • Yan Li,
  • Yingsi Lu,
  • Junhua Qi,
  • Ming Xia,
  • Jinrun Chen,
  • Yingqian Yang,
  • Yazhou Sun,
  • Tianshun Gao,
  • Liping Ye,
  • Qian Liang,
  • Yihang Pan,
  • Chengming Zhu

DOI
https://doi.org/10.1038/s41419-024-06806-3
Journal volume & issue
Vol. 15, no. 6
pp. 1 – 12

Abstract

Read online

Abstract TNF receptor superfamily member 11a (TNFRSF11a, RANK) and its ligand TNF superfamily member 11 (TNFRSF11, RANKL) are overexpressed in many malignancies. However, the clinical importance of RANKL/RANK in colorectal cancer (CRC) is mainly unknown. We examined CRC samples and found that RANKL/RANK was elevated in CRC tissues compared with nearby normal tissues. A higher RANKL/RANK expression was associated with a worse survival rate. Furthermore, RANKL was mostly produced by regulatory T cells (Tregs), which were able to promote CRC advancement. Overexpression of RANK or addition of RANKL significantly increased the stemness and migration of CRC cells. Furthermore, RANKL/RANK signaling stimulated C-C motif chemokine ligand 20 (CCL20) production by CRC cells, leading to Treg recruitment and boosting tumor stemness and malignant progression. This recruitment process was accomplished by CCL20–CCR6 interaction, demonstrating a connection between CRC cells and immune cells. These findings suggest an important role of RANKL/RANK in CRC progression, offering a potential target for CRC prevention and therapy.